
|Articles|February 23, 2011
Gastrointestinal Pipeline Drugs
Advertisement
Credits: 1.0 contact hours (0.10 CEUs)
Michael Marlan Mohundro, PharmD, Director of Pharmacy, Our Lady of the Lake Regional Medical Center
Brice Labruzzo Mohundro, PharmD, Assistant Professor, University of Louisiana at Monroe College of Pharmacy—Baton Rouge Campus
Educational Objectives
After completing this activity, participants should be able to:
- Identify and compare mechanisms of action, safety, tolerability, and efficacy profiles of emerging therapies for common gastrointestinal (GI) disorders
- Recognize the roles of emerging therapies for the treatment of specific GI disorders
Target Audience: This activity is intended for pharmacists—in the community, health systems, or other environments—who treat patients with GI disorders, or any healthcare practitioners who are interested in the availability of new drugs to treat GI disorders.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
emtelligent Turns Unstructured Clinical Data Into Actionable Insights
2
Early Treatment Succeeds in CRC With Next-Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo
3
Real-World Data Show MASH Progresses Faster Than Trials Suggest
4
Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD
5




